Differential plasma proteome analysis in patients with high‑altitude pulmonary edema at the acute and recovery phases

Yang,Yingzhong; Ma,Lan; Guan,Wei; Wang,Yaping; Du,Yang; Ga,Qin; Ge,Ri-Li

doi:10.3892/etm.2014.1548

Differential plasma proteome analysis in patients with high‑altitude pulmonary edema at the acute and recovery phases

Authors:
- Yingzhong Yang
- Lan Ma
- Wei Guan
- Yaping Wang
- Yang Du
- Qin Ga
- Ri-Li Ge
View Affiliations

Affiliations: Research Center for High Altitude Medical Sciences, Qinghai University School of Medicine, Xining, Qinghai 810001, P.R. China
Published online on: February 14, 2014 https://doi.org/10.3892/etm.2014.1548
Pages: 1160-1166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the differential expression of plasma proteins in patients suffering from high‑altitude pulmonary edema (HAPE) at different phases. A complete proteomic analysis was performed using two-dimensional gel electrophoresis followed by mass spectrometry in three patients with HAPE at the acute stage and recovery phase. Comparisons between the expression patterns of the patients with HAPE at the two different phases led to the identification of eight protein spots with a >1.5‑fold difference in expression between the acute and recovery phases. These differentially expressed proteins were apolipoproteins, serum amyloid P component, complement components and others. Apolipoprotein A-I (Apo A‑I), serum amyloid P component and fibrinogen were overexpressed in the patients with HAPE in the acute stage compared with their expression levels in the recovery phase. However, Apo A-IV and antithrombin-III were overexpressed in the patients with HAPE in the recovery phase compared with their expression levels in the acute stage. The results indicate that the differential plasma proteome in patients with HAPE may be associated with the occurrence of HAPE, and the expression changes of Apo A-I and A-IV may offer further understanding of HAPE to aid its prognosis, diagnosis and treatment.

View Figures

View References

1	Hackett PH and Roach RC: High-altitude illness. N Engl J Med. 345:107–114. 2001. View Article : Google Scholar : PubMed/NCBI
2	Basnyat B and Murdoch DR: High-altitude illness. Lancet. 361:1967–1974. 2003. View Article : Google Scholar
3	Mortimer H, Patel S and Peacock AJ: The genetic basis of high-altitude pulmonary oedema. Pharmacol Ther. 101:183–192. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bärtsch P, Mairbäurl H, Maggiorini M and Swenson ER: Physiological aspects of high-altitude pulmonary edema. J Appl Physiol. 98:1101–1110. 2005.
5	Maggiorini M, Mélot C, Pierre S, et al: High altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation. 103:2078–2083. 2001. View Article : Google Scholar : PubMed/NCBI
6	Schoene RB, Hackett PH, Henderson WR, et al: High-altitude pulmonary edema. Characteristics of lung lavage fluid. JAMA. 256:63–69. 1986. View Article : Google Scholar : PubMed/NCBI
7	Schoene RB, Swenson ER, Pizzo CJ, et al: The lung at high altitude: bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol. 64:2605–2613. 1988.PubMed/NCBI
8	Kubo K, Hanaoka M, Yamaguchi S, et al: Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary edema at moderate altitude in Japan. Thorax. 51:739–742. 1996. View Article : Google Scholar : PubMed/NCBI
9	Kubo K, Hanaoka M, Hayano T, et al: Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema. Respir Physiol. 111:301–310. 1998. View Article : Google Scholar : PubMed/NCBI
10	Ran YH, Zhang DX, Xiao ZH, et al: Changes of VEGF, TNF-alpha, IL-6 and NO in serum of patients with HAPE. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 27:201–203. 2011.(In Chinese).
11	Pavlicek V, Marti HH, Grad S, et al: Effects of hypobaric hypoxia on vascular endothelial growth factor and the acute phase response in subjects who are susceptible to high-altitude pulmonary oedema. Eur J Appl Physiol. 81:497–503. 2000. View Article : Google Scholar : PubMed/NCBI
12	Yang X, Xie Y and Zhang D: Research on the relationship between expression of VEGF and high altitude pulmonary edema. Zhonghua Yi Xue Za Zhi. 80:931–935. 2000.(In Chinese).
13	Droma Y, Hayano T, Takabayashi Y, et al: Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Eur Respir J. 9:1947–1949. 1996. View Article : Google Scholar : PubMed/NCBI
14	Honda K, Ono M, Shitashige M, et al: Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol. 43:103–109. 2013. View Article : Google Scholar : PubMed/NCBI
15	Penque D: Two-dimensional gel electrophoresis and mass spectrometry for biomarker discovery. Proteomics Clin Appl. 3:155–172. 2009. View Article : Google Scholar
16	Zhang YY, Duan RF and Wang H: The study of plasma proteomic changes in a patient with high-altitude cerebral edema. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 27:180–184. 2011.(In Chinese).
17	Luo Y, Zhu J and Gao Y: Metabolomic analysis of the plasma of patients with high-altitude pulmonary edema (HAPE) using 1H NMR. Mol Biosyst. 8:1783–1788. 2012. View Article : Google Scholar : PubMed/NCBI
18	Roach RC, Bartsch P, Hackett PH and Oelz O: The Lake Louise acute mountain sickness scoring system. Hypoxia and Molecular Medicine. Sutton JR, Houston CS and Coates G: Burlington, VT: Queens City Printers; pp. 272–274. 1993
19	Hulmes JD, Bethea D, Ho K, et al: An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. Clin Proteomics J. 1:17–31. 2004. View Article : Google Scholar
20	Candiano G, Bruschi M, Musante L, et al: Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 25:1327–1333. 2004. View Article : Google Scholar : PubMed/NCBI
21	Görg A, Obermaier C, Boguth G, et al: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 21:1037–1053. 2000.
22	Yang X, Clifton J, Huang F, et al: Proteomic analysis for process development and control of therapeutic protein separation from human plasma. Electrophoresis. 30:1185–1193. 2009. View Article : Google Scholar : PubMed/NCBI
23	Anderson NL and Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 1:845–867. 2002. View Article : Google Scholar : PubMed/NCBI
24	Ren Y, Cui F, Lei Y, et al: High-altitude pulmonary edema is associated with coagulation and fibrinolytic abnormalities. Am J Med Sci. 344:186–189. 2012. View Article : Google Scholar : PubMed/NCBI
25	Ahmad Y, Shukla D, Garg I, et al: Identification of haptoglobin and apolipoprotein A-I as biomarkers for high altitude pulmonary edema. Funct Integr Genomics. 11:407–417. 2011. View Article : Google Scholar : PubMed/NCBI
26	Garber DW, Handattu SP, Datta G, et al: Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol. 7:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
27	Ma J, Liao XL, Lou B and Wu MP: Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim Biophys Sin (Shanghai). 36:419–424. 2004. View Article : Google Scholar : PubMed/NCBI
28	Yan YJ, Li Y, Lou B and Wu MP: Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci. 79:210–215. 2006. View Article : Google Scholar : PubMed/NCBI
29	Liao XL, Lou B, Ma J and Wu MP: Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci. 77:325–335. 2005. View Article : Google Scholar : PubMed/NCBI
30	Li Y, Dong JB and Wu MP: Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharm. 590:417–422. 2008. View Article : Google Scholar : PubMed/NCBI
31	Bates SR, Tao JQ, Collins HL, Francone OL and Rothblat GH: Pulmonary abnormalities due to ABCA1 deficiency in mice. Am J Physiol Lung Cell Mol Physiol. 289:L980–L989. 2005. View Article : Google Scholar : PubMed/NCBI
32	Yuditskaya S, Tumblin A, Hoehn GT, et al: Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood. 113:1122–1128. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wang W, Xu H, Shi Y, et al: Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res. 51:2560–2570. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kim TH, Lee YH, Kim KH, et al: Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med. 182:633–642. 2010. View Article : Google Scholar : PubMed/NCBI
35	Weng XQ, Huang LY, Lin WT, et al: Effect of intermittent hypoxic exercise on blood-lipid and Apo of rat. China Sport Science. 25(9): 46–48. 2005.(In Chinese).
36	Weinberg RB: Apolipoprotein A-IV polymorphisms and diet-gene interactions. Curr Opin Lipidol. 13:125–134. 2002. View Article : Google Scholar : PubMed/NCBI
37	Fujimoto K, Cardelli JA and Tso P: Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol. 262(6 Pt 1): G1002–1006. 1992.PubMed/NCBI
38	Tso P and Liu M: Apolipoprotein A-IV, food intake, and obesity. Physiol Behav. 83:631–643. 2004. View Article : Google Scholar : PubMed/NCBI
39	Li J, Song M, Qian D, et al: Decreased plasma apolipoprotein A-IV levels in patients with acute coronary syndrome. Clin Invest Med. 36:E207–E215. 2013.PubMed/NCBI
40	Guo Q, Li QY, Wang Y, et al: Research on apo A-IV of obstructive sleep apnea-hypopnea syndrome. Int J Respir. 31:1149–1152. 2011.(In Chinese).